It is also noted that in the 10 patients who developed calcinosis, most had received IVIG and/or rituximab suggesting they had either severe or refractory disease, but none of these patients had received anti-TNF-alpha therapy, since monoclonal antibody forms have been shown to be effective against JDM disease activity and calcinosis [33]. This evidence concerns the gene TNF and juvenile dermatomyositis.